Cover Image
市場調查報告書

Tetraphase Pharmaceuticals Inc.的產品平台分析

Tetraphase Pharmaceuticals Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 251726
出版日期 內容資訊 英文 40 Pages
訂單完成後即時交付
價格
Back to Top
Tetraphase Pharmaceuticals Inc.的產品平台分析 Tetraphase Pharmaceuticals Inc. - Product Pipeline Review - 2015
出版日期: 2015年09月16日 內容資訊: 英文 40 Pages
簡介

Tetraphase Pharmaceuticals Inc.是總公司設於美國的生命科學企業,正在進行抗生劑的研究開發。臨床開發中產品有細菌造成的呼吸疾病和抗藥性病菌的治療藥等。

本報告提供Tetraphase Pharmaceuticals Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Tetraphase Pharmaceuticals Inc.的基本資料

  • Tetraphase Pharmaceuticals Inc.概要
  • 主要資訊
  • 企業資料

Tetraphase Pharmaceuticals Inc.:R&D概要

  • 主要的治療範圍

Tetraphase Pharmaceuticals Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Tetraphase Pharmaceuticals Inc.:開發中產品概況

  • 後期階段產品開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式
  • 開發階段不明的開發中產品
    • 開發階段不明的產品/聯合治療模式

Tetraphase Pharmaceuticals Inc.:藥物簡介

  • eravacycline
  • Small Molecule for Bacterial Infections
  • TP-076
  • TP-138
  • TP-271
  • TP-433
  • TP-559
  • TP-600

Tetraphase Pharmaceuticals Inc.:開發平台分析

  • 按標的
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Tetraphase Pharmaceuticals Inc.:最新的開發平台資訊

Tetraphase Pharmaceuticals Inc.:開發暫停中的計劃

Tetraphase Pharmaceuticals Inc.:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07582CDB

Summary

Global Markets Direct's, 'Tetraphase Pharmaceuticals Inc. - Product Pipeline Review - 2015', provides an overview of the Tetraphase Pharmaceuticals Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Tetraphase Pharmaceuticals Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Tetraphase Pharmaceuticals Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Tetraphase Pharmaceuticals Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Tetraphase Pharmaceuticals Inc.'s pipeline products

Reasons to buy

  • Evaluate Tetraphase Pharmaceuticals Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Tetraphase Pharmaceuticals Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Tetraphase Pharmaceuticals Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Tetraphase Pharmaceuticals Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Tetraphase Pharmaceuticals Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Tetraphase Pharmaceuticals Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Tetraphase Pharmaceuticals Inc. Snapshot
    • Tetraphase Pharmaceuticals Inc. Overview
    • Key Information
    • Key Facts
  • Tetraphase Pharmaceuticals Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Tetraphase Pharmaceuticals Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Tetraphase Pharmaceuticals Inc. - Pipeline Products Glance
    • Tetraphase Pharmaceuticals Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Tetraphase Pharmaceuticals Inc. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Tetraphase Pharmaceuticals Inc. - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
    • Tetraphase Pharmaceuticals Inc. - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Tetraphase Pharmaceuticals Inc. - Drug Profiles
    • eravacycline
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TP-271
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TP-076
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TP-138
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TP-433
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TP-559
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TP-600
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TP-6076
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TP-834
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Tetraphase Pharmaceuticals Inc. - Pipeline Analysis
    • Tetraphase Pharmaceuticals Inc. - Pipeline Products by Target
    • Tetraphase Pharmaceuticals Inc. - Pipeline Products by Route of Administration
    • Tetraphase Pharmaceuticals Inc. - Pipeline Products by Molecule Type
    • Tetraphase Pharmaceuticals Inc. - Pipeline Products by Mechanism of Action
  • Tetraphase Pharmaceuticals Inc. - Recent Pipeline Updates
  • Tetraphase Pharmaceuticals Inc. - Dormant Projects
  • Tetraphase Pharmaceuticals Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Tetraphase Pharmaceuticals Inc., Key Information
  • Tetraphase Pharmaceuticals Inc., Key Facts
  • Tetraphase Pharmaceuticals Inc. - Pipeline by Indication, 2015
  • Tetraphase Pharmaceuticals Inc. - Pipeline by Stage of Development, 2015
  • Tetraphase Pharmaceuticals Inc. - Monotherapy Products in Pipeline, 2015
  • Tetraphase Pharmaceuticals Inc. - Phase III, 2015
  • Tetraphase Pharmaceuticals Inc. - Phase I, 2015
  • Tetraphase Pharmaceuticals Inc. - IND/CTA Filed, 2015
  • Tetraphase Pharmaceuticals Inc. - Preclinical, 2015
  • Tetraphase Pharmaceuticals Inc. - Discovery, 2015
  • Tetraphase Pharmaceuticals Inc. - Unknown, 2015
  • Tetraphase Pharmaceuticals Inc. - Pipeline by Target, 2015
  • Tetraphase Pharmaceuticals Inc. - Pipeline by Route of Administration, 2015
  • Tetraphase Pharmaceuticals Inc. - Pipeline by Molecule Type, 2015
  • Tetraphase Pharmaceuticals Inc. - Pipeline Products by Mechanism of Action, 2015
  • Tetraphase Pharmaceuticals Inc. - Recent Pipeline Updates, 2015
  • Tetraphase Pharmaceuticals Inc. - Dormant Developmental Projects,2015

List of Figures

  • Tetraphase Pharmaceuticals Inc. - Pipeline by Top 10 Indication, 2015
  • Tetraphase Pharmaceuticals Inc. - Pipeline by Stage of Development, 2015
  • Tetraphase Pharmaceuticals Inc. - Monotherapy Products in Pipeline, 2015
  • Tetraphase Pharmaceuticals Inc. - Pipeline by Top 10 Target, 2015
  • Tetraphase Pharmaceuticals Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Tetraphase Pharmaceuticals Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Tetraphase Pharmaceuticals Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top